曼月乐治疗子宫腺肌病患者血清相关指标的变化及疗效分析

Efficacy and the Changes in Related Indexes of Serum for Patients with Adenomyosis with Mirena

目的探讨曼月乐治疗子宫腺肌病效果,并分析患者血清相关指标的变化。方法选取子宫腺肌病患者196例作为研究对象,按随机数字表法分为观察组与对照组,各98例。观察组于月经期第3~5天放置曼月乐环,对照组口服米非司酮。2组患者治疗前、治疗第1、3、6个月检测血清血管内皮生长因子(vascular endothelial growth factor,VEGF)、癌胚抗原125(Carcinoembryonic antigen 125,CA125)及血红蛋白(Hb)水平;图示出血评分法计算月经量评分。结果治疗后第1、3、6个月,观察组CA125水平分别为(89.19±17.46)、(66.31±14.32)和(47.86±11.48)U·mL-1,低于对照组的(97.38±16.47)、(81.29±17.57)和(72.36±15.54)U·mL-1,差异均有统计学意义(P<0.05);观察组治疗后第1、3、6个月时,VEGF水平分别为(149.35±17.34)、(131.77±16.76)和(121.58±15.47)ng·L-1,低于对照组的(169.46±21.43)、(151.32±18.43)和(142.37±17.35)ng·L-1,差异均有统计学意义(P<0.05);治疗后第1、3、6个月时,观察组Hb水平分别为(91.36±9.35)、(107.49±9.67)和(119.87±8.48)g·L-1,高于对照组的(85.37±10.73)、(98.46±9.54)和(106.55±9.92)g·L-1,差异均有统计学意义(P<0.05)。结论曼月乐对子宫腺肌病患者的疗效较传统疗法更为有效。

Objective To discuss the effect of Mirena in the treatment of adenomyosis,and analyze the changes of patients’serum related indexes Methods Results Conclusion Mirena is more effective in treating adenomyosis patients than traditional therapies.Methods 196 patients with adenomyosis were selected as the research objects,and randomly divided into the observation group(98 cases)and the control group(98 cases)according to random number table method.The observation group placed Mirena during the 3rd to 5th day of menstrual period,and the control group took mifepristone orally.Both groups detected the levels of serum vascular endothelial growth factor(VEGF),carcinoembryonic antigen 125(CA125)and hemoglobin(Hb)at the 1st,3rd and 6th month before treatment and after treatment,and graphical bleeding score method calculated menstrual volume score.Results There was no significant difference in the levels The levels of CA125 in the observation group were(89.19±17.46),(66.31±14.32)and(47.86±11.48)U·mL-1 at 1,3,and 6 months after treatment,respectively,which were lower than the control group(97.38±16.47),(81.29±17.57)and(72.36±15.54)U·mL-1.The differences were statistically significant(P<0.05).The levels of VEGF in the observation group were(149.35±17.34),(131.77±16.76)and(121.58±15.47)ng·L-1 at the 1st,3rd and 6th month after treatment,respectively,which were lower than the control group(169.46±21.43),(151.32±18.43)and(142.37±17.35)ng·L-1.The differences were statistically significant(P<0.05).The levels of Hb in the observation group were(91.36±9.35),(107.49±9.67)and(119.87±8.48)g·L-1 at the 1st,3rd and 6th month after treatment,respectively,which were higher than the control group(85.37±10.73),(98.46±9.54)and(106.55±9.92)g·L-1,the differences were statistically significant(P<0.05).Conclusion Manyuele is more effective in treating adenomyosis patients than traditional therapies.It can significantly reduce serum VEGF and CA125 levels and increase serum Hb levels.